

Yves Albert DeClerck

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4161574/yves-albert-declerck-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87
papers

6,068
citations

45
h-index

77
g-index

95
ext. papers

6,917
ext. citations

8
avg, IF

5.76
L-index

#	Paper	IF	Citations
87	The Tumor Microenvironment in Neuroblastoma: New Players, New Mechanisms of Interaction and New Perspectives. <i>Cancers</i> , 2020 , 12,	6.6	17
86	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020 , 182, 1044-1061	6.18	288
85	Cancer-Associated Fibroblasts: Understanding Their Heterogeneity. <i>Cancers</i> , 2020 , 12,	6.6	29
84	Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells. <i>Clinical Cancer Research</i> , 2019 , 25, 4761-4774	12.9	29
83	The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding. <i>Cancer and Metastasis Reviews</i> , 2019 , 38, 483-492	9.6	47
82	Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. <i>Cell Reports</i> , 2018 , 25, 2177-2191.e7	10.6	51
81	Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells. <i>Journal of Extracellular Vesicles</i> , 2017 , 6, 1332941	16.4	34
80	Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2516-2527	6.1	11
79	Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment. <i>Journal of Visualized Experiments</i> , 2017 ,	1.6	2
78	Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. <i>Cancer Research</i> , 2017 , 77, 5142-5157	10.1	89
77	Paternal Risk Factors for Oral Clefts in Northern Africans, Southeast Asians, and Central Americans. <i>International Journal of Environmental Research and Public Health</i> , 2017 , 14,	4.6	5
76	Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. <i>Oncotarget</i> , 2017 , 8, 91516-91529	3.3	31
75	Fat, Calories, and Cancer. <i>Cancer Research</i> , 2016 , 76, 509-10	10.1	5
74	More than the genes, the tumor microenvironment in neuroblastoma. <i>Cancer Letters</i> , 2016 , 380, 304-14	9.9	46
73	Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. <i>Cancer Research</i> , 2015 , 75, 2969-74	10.1	93
72	The Tumor Microenvironment as a Target for Therapeutic Intervention 2015 , 47-63		
71	Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. <i>PLoS ONE</i> , 2015 , 10, e0133786	3.7	29

70	Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis. <i>International Journal of Cancer</i> , 2015 , 137, 797-809	7.5	10
69	Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 962-75	6.1	52
68	MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival. <i>Cancer Research</i> , 2014 , 74, 5999-6009	10.1	8
67	Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. <i>Cancer Research</i> , 2013 , 73, 4965-77	10.1	191
66	Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. <i>Cancer Research</i> , 2013 , 73, 3852-64	10.1	96
65	Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells. <i>Osteoporosis International</i> , 2012 , 23, 1399-413	5.3	37
64	Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1470-84	9.7	65
63	Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF- κ B signaling, and synergizes with an ERK inhibitor. <i>Cancer Biology and Therapy</i> , 2012 , 13, 349-57	4.6	26
62	Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. <i>Cancer Biology and Therapy</i> , 2012 , 13, 534-41	4.6	21
61	Desmoplasia: a response or a niche?. <i>Cancer Discovery</i> , 2012 , 2, 772-4	24.4	45
60	A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. <i>Cancer Research</i> , 2012 , 72, 2228-38	10.1	57
59	Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice. <i>Life Sciences</i> , 2011 , 88, 693-700	6.8	22
58	A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. <i>Pediatric Blood and Cancer</i> , 2011 , 57, 275-82	3	34
57	Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. <i>Clinical Cancer Research</i> , 2011 , 17, 7093-104	12.9	32
56	Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). <i>Cancer Biology and Therapy</i> , 2010 , 10, 198-208	4.6	29
55	Interleukin-6 in bone metastasis and cancer progression. <i>European Journal of Cancer</i> , 2010 , 46, 1223-31	7.5	265
54	Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. <i>Cancer and Metastasis Reviews</i> , 2010 , 29, 249-61	9.6	264
53	The Extracellular Matrix and the Growth and Survival of Tumors 2010 , 695-710		

52	Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. <i>Cancer Research</i> , 2009 , 69, 329-37	10.1	139
51	Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1524-36	15.9	215
50	Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. <i>Cancer Cell</i> , 2008 , 14, 324-34	24.3	107
49	Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. <i>Journal of Biological Chemistry</i> , 2008 , 283, 18573-81	5.4	52
48	Bone marrow microenvironment and tumor progression. <i>Cancer Microenvironment</i> , 2008 , 1, 23-35	6.1	50
47	The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. <i>Cancer Research</i> , 2007 , 67, 9346-55	10.1	32
46	The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest. <i>Journal of Biological Chemistry</i> , 2007 , 282, 24471-6	5.4	30
45	Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2702-12	15.9	75
44	Mechanisms of invasion and metastasis in human neuroblastoma. <i>Cancer and Metastasis Reviews</i> , 2006 , 25, 645-57	9.6	62
43	Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. <i>Cancer Research</i> , 2006 , 66, 2691-9	10.1	52
42	Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. <i>European Journal of Cancer</i> , 2006 , 42, 310-8	7.5	112
41	Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model. <i>Journal of Computer Assisted Tomography</i> , 2006 , 30, 525-34	2.2	25
40	Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. <i>Cancer and Metastasis Reviews</i> , 2006 , 25, 35-43	9.6	180
39	Mechanisms of bone invasion and metastasis in human neuroblastoma. <i>Cancer Letters</i> , 2005 , 228, 203-9	9.9	49
38	The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. <i>Cancer Research</i> , 2005 , 65, 3200-8	10.1	137
37	Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy. <i>Cancer Cell</i> , 2005 , 7, 408-9	24.3	3
36	Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. <i>Cancer Research</i> , 2005 , 65, 1129-35	10.1	66
35	Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. <i>Journal of Biological Chemistry</i> , 2005 , 280, 40187-94	5.4	63

34	Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation. <i>Journal of Biological Chemistry</i> , 2004 , 279, 8592-601	5.4	107
33	Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. <i>Cancer Research</i> , 2004 , 64, 1675-86	10.1	187
32	Focus on the cell membrane: the need for dissociation and detachment in tumoral invasion. <i>Cancer Biology and Therapy</i> , 2004 , 3, 632-3	4.6	
31	The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. <i>Cancer Research</i> , 2004 , 64, 2328-32	10.1	92
30	TIMP-2 is released as an intact molecule following binding to MT1-MMP on the cell surface. <i>Experimental Cell Research</i> , 2004 , 293, 164-74	4.2	25
29	Proteases, extracellular matrix, and cancer: a workshop of the path B study section. <i>American Journal of Pathology</i> , 2004 , 164, 1131-9	5.8	179
28	Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. <i>Cancer Gene Therapy</i> , 2003 , 10, 435-44	5.4	25
27	Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. <i>Journal of Histochemistry and Cytochemistry</i> , 2003 , 51, 151-8	3.4	55
26	Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. <i>Cancer Research</i> , 2003 , 63, 3026-31	10.1	28
25	Les mBalloprotBses matricielles et leurs inhibiteurs synthBiques dans la progression tumorale. <i>Medecine/Sciences</i> , 2002 , 18, 565-575		8
24	Tissue Inhibitors of Metalloproteinases in Cancer 2002 , 169-194		
23	TGF-beta3-induced palatogenesis requires matrix metalloproteinases. <i>Molecular Biology of the Cell</i> , 2001 , 12, 1457-66	3.5	137
22	Magnetic resonance imaging for the evaluation of a novel metastatic orthotopic model of human neuroblastoma in immunodeficient mice. <i>Clinical and Experimental Metastasis</i> , 2000 , 18, 455-61	4.7	14
21	Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. <i>Journal of Biological Chemistry</i> , 2000 , 275, 41415-23	5.4	104
20	NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2. <i>Journal of Biological Chemistry</i> , 2000 , 275, 18602-10	5.4	42
19	Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 10026-31	11.5	141
18	Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV. <i>Journal of Biological Chemistry</i> , 1999 , 274, 4421-9	5.4	66
17	Tissue inhibitors of matrix metalloproteinases in cancer. <i>Annals of the New York Academy of Sciences</i> , 1999 , 878, 108-19	6.5	72

16	Identification of the TIMP-2 binding site on the gelatinase A hemopexin C-domain by site-directed mutagenesis and the yeast two-hybrid system. <i>Annals of the New York Academy of Sciences</i> , 1999 , 878, 747-53	6.5	9
15	Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. <i>Apmis</i> , 1999 , 107, 111-9	3.4	105
14	Urokinase induces receptor mediated brain tumor cell migration and invasion. <i>Journal of Neuro-Oncology</i> , 1998 , 40, 215-26	4.8	26
13	Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). <i>Journal of Biological Chemistry</i> , 1998 , 273, 1216-22	5.4	235
12	The C-terminal domain of tissue inhibitor of metalloproteinases-2 is required for cell binding but not for antimetalloproteinase activity. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 236, 100-5	3.4	14
11	Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases. <i>Gynecologic Oncology</i> , 1997 , 67, 277-84	4.9	19
10	Proteases and protease inhibitors in tumor progression. <i>Advances in Experimental Medicine and Biology</i> , 1997 , 425, 89-97	3.6	92
9	Cloning and partial structure of the gene encoding human tissue inhibitor of metalloproteinases-3. <i>Gene</i> , 1996 , 170, 287-8	3.8	7
8	Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. <i>Enzyme & Protein</i> , 1996 , 49, 72-84		81
7	Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. <i>Journal of Cellular Physiology</i> , 1996 , 167, 333-40	7	27
6	Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. <i>Journal of Biological Chemistry</i> , 1996 , 271, 25498-505	5.4	86
5	Purification and characterization of a collagenase inhibitor produced by bovine vascular smooth muscle cells. <i>Archives of Biochemistry and Biophysics</i> , 1988 , 265, 28-37	4.1	36
4	Primary central nervous system lymphoma without intracranial mass in a child. Diagnosis by documentation of monoclonality. <i>Cancer</i> , 1985 , 56, 2804-8	6.4	25
3	Macrocytosis and pure RBC anemia caused by azathioprine. <i>JAMA Pediatrics</i> , 1980 , 134, 377-9		6
2	A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. <i>Cancer</i> , 1979 , 44, 896-8	6.4	69
1	Hemophilus influenzae type b infections: recurrent disease due to ampicillin-resistant strains. <i>Journal of Pediatrics</i> , 1977 , 90, 319-20	3.6	11